3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 230 points (-1.3%) at 17,680 as of Monday, Nov. 9, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 442 issues advancing vs. 2,580 declining with 96 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 1.3%. On the negative front, top decliners within the industry include

Mallinckrodt

(

MNK

), down 6.7%,

Biomarin Pharmaceutical

(

BMRN

), down 3.1%,

Sanofi

(

SNY

), down 3.0%,

Perrigo

(

PRGO

), down 2.8% and

Celgene

(

CELG

), down 2.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Medivation

(

MDVN

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Medivation is up $2.50 (6.3%) to $42.02 on average volume. Thus far, 960,871 shares of Medivation exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $39.60-$42.07 after having opened the day at $39.61 as compared to the previous trading day's close of $39.53.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $7.1 billion and is part of the health care sector. Shares are down 20.6% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Medivation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Medivation

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full

Medivation Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Alnylam Pharmaceuticals

(

ALNY

) is up $5.60 (5.5%) to $107.13 on average volume. Thus far, 525,470 shares of Alnylam Pharmaceuticals exchanged hands as compared to its average daily volume of 967,000 shares. The stock has ranged in price between $98.47-$108.00 after having opened the day at $99.95 as compared to the previous trading day's close of $101.53.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Alnylam Pharmaceuticals has a market cap of $8.4 billion and is part of the health care sector. Shares are up 4.7% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Alnylam Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share. Get the full

Alnylam Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Incyte

(

INCY

) is up $3.26 (3.2%) to $103.47 on heavy volume. Thus far, 1.4 million shares of Incyte exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $101.50-$108.29 after having opened the day at $101.50 as compared to the previous trading day's close of $100.21.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. Incyte has a market cap of $21.7 billion and is part of the health care sector. Shares are up 37.1% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Incyte a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Incyte

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk and feeble growth in its earnings per share. Get the full

Incyte Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...